A Phase 1 Study to Investigate the Mass Balance of [14C]-Nanatinostat and to Evaluate the Relative Bioavailability of Nanatinostat in Patients With Selected Advanced Cancers

This study will determine how nanatinostat is absorbed, modified, and removed from the body (Part A), the amount of nanatinostat that becomes available to the body (Part B), and will evaluate the safety and tolerability of nanatinostat (Part C) in patients with advanced cancers.

开始日期2024-02-28

申办/合作机构

Viracta Therapeutics, Inc.

NCT05166577

/ Terminated临床1期

Open-Label Multicenter Phase 1b/2 Study of Nanatinostat + Valganciclovir in Patients With Advanced Epstein-Barr Virus-Positive Solid Tumors and in Combination With Pembrolizumab in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

This study will evaluate the safety and efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive solid tumors and in combination with pembrolizumab in patients with recurrent/metastatic nasopharyngeal carcinoma

开始日期2021-10-08

申办/合作机构

Viracta Therapeutics, Inc.

NCT05011058

/ Terminated临床2期

An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas

A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas

开始日期2021-05-28

申办/合作机构

Viracta Therapeutics, Inc.

100 项与 Tractinostat 相关的临床结果

登录后查看更多信息

100 项与 Tractinostat 相关的转化医学

登录后查看更多信息

100 项与 Tractinostat 相关的专利（医药）

登录后查看更多信息

项与 Tractinostat 相关的文献（医药）

2026-10-01·JOURNAL OF MOLECULAR MODELING

Structure-guided identification of histone deacetylase 11 inhibitors for targeted chemotherapy through long-timescale molecular dynamics simulation

Article

作者: Ponnusamy, Chandra Sekar ; Ravindran, Nevedha ; Maiti, Koustav ; Chakraborty, Deotima ; Gnanasekar, Heshine ; Velusamy, Mahesh ; Sridharan, Bhavani

CONTEXT:

Histone deacetylase 11 (HDAC11), the sole member of class IV histone deacetylases, is an emerging epigenetic target in cancer therapy. In this study, an integrated computational approach involving ADMET screening, molecular docking, and molecular dynamics simulations was employed to identify potential HDAC11 inhibitors from 35 known HDAC inhibitors. Based on combined docking and pharmacokinetic analyses, five compounds were shortlisted for detailed evaluation. Mocetinostat exhibited the highest binding affinity toward HDAC11 (-8.70 kcal/mol) with acceptable pharmacokinetic properties (LogP: 2.25; TPSA: 99.11 Å²), while Belinostat showed the safest toxicity profile (LD50: 6000 mg/kg; Class 6). Resminostat also demonstrated favorable drug-likeness with moderate toxicity (LD50: 957 mg/kg; Class 4). Comparative MD analyses over 500 ns revealed high structural stability for the Nanatinostat-HDAC11 and Resminostat-HDAC11 complexes by lower RMSD, reduced residue fluctuations, and more stable hydrogen bond interactions. These findings highlight promising HDAC11 inhibitors for further experimental validation in anticancer drug development.

METHODS:

The HDAC11 protein structure was prepared and optimized along with ligand structures prior to docking. Pharmacokinetic properties and drug-likeness of all 35 selected HDAC inhibitors were predicted using the SwissADME web server, and toxicity profiles were assessed using the Protox-II server. Molecular docking was performed using PyRx with the AutoDock Vina scoring function. Protein-ligand interactions were analyzed using PyMOL and Discovery Studio visualizers. Molecular dynamics simulations were conducted using GROMACS with the CHARMM27 force field and TIP3P water model. A total of 3.5 µs of molecular dynamics simulations were performed, including a 500 ns production run and triplicate 100 ns validation runs for each complex. MD trajectory analyses, including RMSD, RMSF, radius of gyration, solvent-accessible surface area, hydrogen bond analysis, and kernel density estimation, were used to evaluate structural stability and interaction dynamics.

2026-09-01·Clinical and Translational Medicine

4‐Hydroxytamoxifen induces a noncanonical ferroptosis in lung adenocarcinoma by targeting AKR1B10

Article

作者: Chen, Shengsong ; Wang, Yanan ; Jin, Jiangbo ; Xu, Hanyan ; Zhan, Qingyuan ; Miao, Yinshui ; Han, Tianyu ; Yang, Hui ; Wu, Xiaojing

Abstract:

Background:

Lung adenocarcinoma (LUAD) remains a leading cause of cancer mortality, and current therapies are limited by drug resistance and toxicity. Ferroptosis offers an attractive strategy for cancer therapy, but classical ferroptosis is iron‑dependent. Repurposing approved drugs offers a rapid strategy to identify novel anti‑LUAD agents, yet the mechanism by which 4‑Hydroxytamoxifen (4‑OHT) exerts estrogen receptor–independent anti‑tumour effects remains unclear.

Methods:

We performed a drug repurposing screen of 950 endogenous metabolites in LUAD cells.Anti‑tumour activity was validated in vitro and in vivo using LUAD cell lines and mouse models. Target identification and mechanistic studies employed LiP‑MS, pull‐down SPR, CETSA, metabolomics, and enzyme activity assays. Clinical relevance was assessed via tissue microarrays and TCGA analysis. Drug synergy was quantified using the Chou–Talalay method.

Results:

4‑OHT inhibited LUAD cell proliferation with IC 50 values of 3.86 ± 0.26 µM to 13.58 ± 0.55 µM independent of estrogen receptor. It triggered noncanonical ferroptosis characterised by GSH depletion (reduced by about 60%), GPX4 downregulation, lipid peroxidation (about 2.5‐fold increase), and iron independence. Mechanistically, 4‑OHT directly bound AKR1B10 (K D (M) was 7.98e‐06) and inhibited its enzymatic activity, leading to ACC1 degradation, lipid deficiency, and accumulation of toxic lipid‑derived carbonyls. AKR1B10 knockout abolished 4‑OHT‑induced cell death, while rescue restored sensitivity. Nanatinostat similarly targeted AKR1B10 and induced the same cell death modality. AKR1B10 upregulation in LUAD tissues correlated with reduced overall survival rates.

Conclusion:

This study demonstrates that 4‑OHT directly inhibits AKR1B10 enzymatic activity to induce a noncanonical ferroptosis in LUAD. AKR1B10 overexpression correlates with poor prognosis and chemoresistance in LUAD patients. Nonetheless, AKR1B10 inhibition warrants further investigation as a therapeutic strategy.

Highlights:

4‑OHT directly inhibits AKR1B10 enzymatic activity to induce noncanonical ferroptosis in LUAD.AKR1B10 sustains LUAD survival by stabilising ACC1 and detoxifying reactive carbonyl species (RCSs).Nanatinostat similarly targets AKR1B10 and elicits the same cell death modality.AKR1B10 overexpression correlates with poor prognosis and chemoresistance in LUAD.

2026-08-01·JOURNAL OF MEDICAL VIROLOGY

Clinical‐Stage Nanatinostat Triggers Productive Epstein‐Barr Virus Lytic Replication

Article

作者: Bhaduri‐McIntosh, Sumita ; Willman, Griffin H. ; Patel, Devshree ; El‐Guindy, Ayman ; Akinyemi, Ibukun A. ; Zeigler, Travis M. ; McIntosh, Michael T.

ABSTRACT:

A phase 1b/2 study of the all‐oral “kick‐and‐kill” combo nanatinostat + valganciclovir (nana‐val) showed a ~40% overall response rate in patients with relapsed/refractory Epstein‐Barr virus (EBV)‐associated lymphomas. Despite the promising results in these difficult‐to‐treat cancers, there is little known about the effects of nanatinostat on EBV and cell death. In this work we demonstrate that nanatinostat, an HDAC1/3 inhibitor, robustly induces the full EBV lytic cycle in a panel of EBV‐positive lymphoma and transformed cell lines (Burkitt, DLBCL, lymphoblastoid), spanning viral latency types and EBV genotypes. Nanatinostat drives lytic‐gene transcription across all kinetic classes, viral genome replication, and virion release, and kills cells at nanomolar concentrations. Although valganciclovir does not increase cytotoxicity, its ability to block viral DNA synthesis and virion production justifies its inclusion to prevent viral dissemination. Importantly, the two main metabolites of nanatinostat lack histone‐H3 acetylation activity and neither activate nor inhibit the EBV lytic phase, indicating that they are biologically inert with respect to EBV. These mechanistic insights clarify the clinical efficacy of nana‐val and support further development of kick‐and‐kill strategies for EBV‐driven malignancies.

项与 Tractinostat 相关的新闻（医药）

2026-09-09

·今日头条

诱导发生非典型铁死亡！南昌大学第一附属医院发文：潜在的肺腺癌治疗策略

9月8日，南昌大学第一附属医院研究团队在期刊《Clinical And Translational Medicine》上发表了研究论文，题为“4-Hydroxytamoxifen induces a noncanonical ferroptosis in lung adenocarcinoma by targeting AKR1B10”，本研究证实，4-OHT可直接抑制AKR1B10的酶活性，从而在肺腺癌（LUAD）中诱导非经典型铁死亡。AKR1B10的高表达与LUAD患者的预后不良和耐药性相关。然而，抑制AKR1B10作为治疗策略仍有待进一步研究。直面肺腺癌耐药与复发难题：探索更优患者预后的新治疗靶点 01 肺腺癌（LUAD）是非小细胞肺癌（NSCLC）的主要组织学亚型，已成为全球重大的健康负担，其发病率持续上升，死亡率居高不下。目前针对LUAD的治疗策略常面临药物耐药、复发和严重副作用等严峻挑战，限制了整体疗效和患者生存率。因此，亟需开发新的治疗靶点和策略，以改善LUAD患者的预后。 NANA抑制剂还通过靶向 AKR1B10 诱导非经典铁死亡 02 为了确定其他药物或化合物是否通过靶向AKR1B10诱导非经典铁死亡，研究人员以AKR1B10为靶蛋白，在药物再利用化合物库（6242种化合物）和天然产物库（6255种化合物）中进行了高通量虚拟筛选。研究人员从各库中排名前200的化合物中选取了每个库的前50种化合物（去除部分重复化合物，共76种）进行细胞活力检测。研究显示，部分化合物能有效抑制A549细胞的活力，其中Nanatinostat（NANA）表现出最强的抑制活性。NANA是一种选择性I类组蛋白去乙酰化酶抑制剂，但其在肺癌中的作用尚不明确。研究人员发现NANA可有效抑制LUAD细胞的活力，其IC50值低于1 µM。分子对接结果显示，NANA与AKR1B10在Tyr49、Gln184和Asp217位点形成氢键。CETSA实验表明，NANA处理后AKR1B10的稳定性增强，提示NANA在细胞内与AKR1B10发生结合。AKR1B10的体外活性检测表明，NANA能有效抑制其酶活性，且该抑制效果优于‌依帕司他。使用靶向经典程序性细胞死亡形式的特异性抑制剂进行挽救实验发现，除棕榈酸（PA）外，其他抑制剂均无法持续挽救NANA诱导的细胞死亡。随后研究人员检测了脂质过氧化水平，研究显示，NANA处理显著增加了A549和H1299细胞中的脂质过氧化水平。此外，NANA处理还以浓度依赖的方式降低了ACC1和GPX4的表达。综上所述，这些结果表明，NANA通过靶向AKR1B10诱导了一种非经典的铁死亡。 NANA还通过靶向 AKR1B10 诱导非经典铁死亡 4-OHT与产生RCSs的化疗药物具有协同作用 03 据报道，AKR1B10通过减少某些化疗药物（如卡铂和紫杉醇）发挥细胞毒性所必需的特定羰基，或减少细胞毒性RCSs的产生，从而促进癌细胞的化疗耐药性。研究人员希望探讨4-OHT是否能协同增强产生细胞毒性RCSs的化疗药物的抗癌效果。在LUAD细胞中，卡铂和紫杉醇均能有效抑制细胞活力，且4-OHT协同增强了卡铂和紫杉醇的疗效。鉴于随后的体内实验是使用LLC同基因模型进行的，研究人员首先在LLC细胞中验证了这种协同效应。与单药治疗相比，4-OHT和卡铂的联合用药显著增强了抗肿瘤效果，且未对小鼠体重产生不利影响。总而言之，这些发现表明4-OHT能与产生RCSs的化疗药物产生协同作用。结论 04 本研究表明，4-OHT通过抑制AKR1B10的酶活性诱导LUAD发生非典型铁死亡。NANA同样靶向AKR1B10并引发相同的死亡方式，且AKR1B10的过表达与LUAD患者的预后不良和化疗耐药相关。这些发现提示AKR1B10抑制可作为一种潜在的治疗策略，但其潜在机制仍需进一步研究。参考资料： https://onlinelibrary.wiley.com/doi/10.1002/ctm2.70796 【关于投稿】转化医学网（360zhyx.com）是转化医学核心门户，旨在推动基础研究、临床诊疗和产业的发展，核心内容涵盖组学、检验、免疫、肿瘤、心血管、糖尿病等。如您有最新的研究内容发表，欢迎联系我们进行免费报道（公众号菜单栏-在线客服联系），我们的理念：内容创造价值，转化铸就未来！转化医学网（360zhyx.com）发布的文章旨在介绍前沿医学研究进展，不能作为治疗方案使用；如需获得健康指导，请至正规医院就诊。责任声明：本稿件如有错误之处，敬请联系转化医学网客服进行修改事宜！微信号：zhuanhuayixue

2026-06-28

·研日新

研日新日报 ·3| 06月29日全科医学 | 血液内科 | 皮肤科

日报精选医学文献今日精选20篇医学文献，查看更多请点击阅读原文本文支持继续浏览摘要内容；完整摘要、收藏文章、订阅管理等完整功能，请前往小程序「医研日新」。前往小程序查看更多与订阅收藏 1. A Multiepitope Intranasal Adenoviral Vaccine Induces Robust Mucosal Immunity and Protection against SARS‑CoV‑2. [COVID-19] Journal of nanobiotechnology | 2026-06-27 | IF 10.6 AI鼻内接种多表位腺病毒疫苗可能提供针对多种SARS-CoV-2变异株的广谱保护，尤其对Omicron变异株有效，为下一代黏膜疫苗研发提供了有前景的临床转化价值。摘要Vaccination has been central to mitigating the COVID-19 pandemic; however, the continual emergence of SARS-CoV-2 variants of concern (VOCs) has reduced the effectiveness of current intramuscular vaccines that primarily target the Spike (S) protein. Although updated formulations are periodically introduced, there remains a critical need for next-generation vaccine platforms capable of inducing broa...查看完整摘要 2. Natural product emodin-based nanodrug delivery systems: advancements and applications. [Obesity] 综述 | Pharmacological research | 2026-06-27 | IF 9.1 AI大黄素纳米递送系统有望突破传统剂型的局限性，为肿瘤、炎症及纤维化等难治性疾病提供新型治疗策略，但实现临床转化仍需解决规模化生产与质量控制等关键问题。摘要Emodin, a natural anthraquinone derivative, possesses diverse pharmacological activities encompassing anticancer, antibacterial, anti-inflammatory, antiviral, antifibrosis, and antioxidant effects. Nevertheless, its clinical application is severely impeded due to its poor water solubility, inadequate stability, low bioavailability, and potential dose-dependent toxicity. To address these challenges...查看完整摘要 3. Corrigendum to "Mechanistic insights into the role of USP14 in adipose tissue macrophage recruitment and insulin resistance in obesity" [Int. J. Biol. Macromol. 267 (2024) 131645]. [Obesity] Published Erratum | International journal of biological macromolecules | 2026-06-27 | IF 7.7 AIUSP14可能是肥胖相关胰岛素抵抗的潜在治疗靶点，靶向抑制该酶或可改善脂肪组织炎症和代谢功能。 4. Cardiac organoids in toxicology: from construction strategies and research trends to precision screening applications. [Cardiovascular Diseases] 综述 | Stem cell research & therapy | 2026-06-27 | IF 7.1 AI心脏类器官为临床前心脏毒性筛选提供了高仿生人源化模型，有望显著提升药物安全性评估的准确性，降低临床试验风险，为精准医学时代的心血管药物开发与安全性评价提供革命性工具。摘要Cardiovascular diseases (CVDs) are the leading cause of death worldwide, with significant attention focused on the development of therapeutic drugs and research into pathogenic mechanisms. In the real world, cardiotoxicity induced by multiple factors commonly exists and is closely associated with cardiovascular diseases. Traditional toxicity testing models (such as animal experiments and two-dimen...查看完整摘要 5. Chronic semaglutide alters ingestive behavior without impairing taste function in mice. [Obesity] Molecular metabolism | 2026-06-27 | IF 7.0 AI司美格鲁肽的减重机制可能主要通过调节摄食动机而非改变味觉感知实现，临床应用时无需担忧味觉功能损害。摘要Glucagon-like peptide-1 receptor (GLP-1R) agonists such as semaglutide are highly effective treatments for obesity, yet the mechanisms by which they reduce food intake remain incompletely understood. Because taste plays a critical role in guiding food intake, several clinical studies have investigated whether GLP-1R agonists alter taste function, but these reports have yielded conflicting results....查看完整摘要 6. Dual functional genomics reveals a broad and convergent landscape of asciminib resistance in BCR::ABL1. [Leukemia] Genome medicine | 2026-06-27 | IF 11.2 AI阿西米尼耐药突变可发生于SH3和SH2域，临床耐药监测应超越激酶域，扩展至整个BCR::ABL1蛋白。摘要Drug resistance is a constantly evolving challenge. The allosteric inhibitor asciminib is a novel therapy for chronic myelogenous leukemia (CML) that targets the myristoyl pocket of the BCR::ABL1 kinase. While it can overcome resistance to active-site inhibitors like imatinib, new resistance mutations to asciminib are emerging. The complete landscape of these mutations, particularly those outside ...查看完整摘要 7. Targeting EBV-associated gastric cancer by lytic induction therapy with nanatinostat. [Lymphoma] Tumour virus research | 2026-06-27 | IF 8.1 AINSTAT联合GCV的溶瘤诱导策略为既往缺乏有效靶向治疗的EBV阳性胃癌提供了全新的精准治疗方向，临床转化前景值得期待。摘要Latent Epstein-Barr virus (EBV) infection is associated with multiple lymphoid and epithelial cancers in humans. Targeting EBV through lytic induction therapy represents a potential strategy for treating virus-associated malignancies, such as EBV-associated gastric cancer (EBVaGC). Despite its classification as a distinct gastric cancer subtype, precision therapeutic strategies for EBVaGC remain v...查看完整摘要 8. Plant-derived L-asparaginases: Comprehensive functional and biological characterization. [Leukemia] International journal of biological macromolecules | 2026-06-27 | IF 7.7 AIPvAIII(K)-1作为植物来源的III型L-天冬酰胺酶，在保持高抗白血病活性的同时显著降低了对正常细胞和L-谷氨酰胺酶的活性，提示其具有作为急性淋巴细胞白血病治疗候选药物的潜力。摘要In this study, K-dependent and K-independent plant-derived type III L-asparaginases from Arabidopsis thaliana (AtAIII, AtAIII(K)) and Phaseolus vulgaris (PvAIII, PvAIII(K)-1) were systematically tested for their catalytic properties, structural stability (Tm), and antiproliferative and proapoptotic activity in human leukemia cell lines. Among them, the K-dependent enzyme PvAIII(K)-1 sho...查看完整摘要 9. Targeting CCR7-KMT2D enhances CAR-T cell efficacy by suppressing therapy-induced senescence in B-cell non-Hodgkin lymphoma. [Lymphoma] BMC medicine | 2026-06-26 | IF 7.0 AIB-NHL患者CAR-T治疗前检测CCR7表达水平，结合CCR7抑制剂（如Cap-100）可能通过抑制治疗诱导衰老、增强T细胞功能来克服耐药，为改善CAR-T疗效提供新策略。摘要The efficacy of anti-CD19 Chimeric Antigen Receptor (CAR) T-cell therapy has been demonstrated in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). However, therapy-induced senescence (TIS) has been identified as a novel resistance mechanism, potentially exacerbating immunosuppression and impairing CAR-T cell function. Raji and SU-DHL-2 cells were treated with 40 nM doxorub...查看完整摘要 10. Neutrophil extracellular traps in thrombosis of hematologic malignancies: Underlying mechanisms and therapeutic opportunities (Review). [Multiple Myeloma] 综述 | International journal of molecular medicine | 2026-06-26 | IF 5.7 AINET可能是血液系统恶性肿瘤患者血栓风险评估和抗凝治疗策略优化的有价值的生物标志物和治疗靶点。摘要Patients with cancer, particularly those diagnosed with hematological malignancies, exhibit thrombus incidence rates that exceed those observed in the general population by a substantial margin, and this elevated risk is associated with worse clinical outcomes. Neutrophil extracellular traps (NETs), which are web‑like structures released by neutrophils as part of their innate immune repertoire, dr...查看完整摘要 11. JAAD Game Changers: "Negative impact of comorbidities on all-cause mortality of patients with psoriasis is partially alleviated by biologic treatment: A real-world case-control study". [Psoriasis] Journal of the American Academy of Dermatology | 2026-06-27 | IF 12.8 AI生物制剂治疗可部分抵消合并症带来的死亡风险增加，提示对合并症负担较重的银屑病患者应早期启动生物制剂治疗以改善预后。 12. JAAD Game Changers: "Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial". [Dermatitis] Journal of the American Academy of Dermatology | 2026-06-27 | IF 12.8 AI罗氟司特泡沫剂作为首个获批用于脂溢性皮炎的PDE4抑制剂，为中重度患者提供了一种有效、安全且耐受性良好的局部治疗新选择。 13. Apoptosis-mediated anti-leishmanial activity of azurin: An integrated in silico and in vitro investigation. [Leishmaniasis] International journal of biological macromolecules | 2026-06-27 | IF 7.7 AI天青蛋白在低浓度下即可通过诱导细胞凋亡机制有效杀灭利什曼原虫，IC50值约为20.72 μg/mL，具备成为新型抗利什曼病药物的潜力。摘要Leishmaniasis is a neglected tropical protozoan disease that exists in several parts of the world. The current therapies and treatments available have numerous shortcomings, and to tackle this, there is a need for potential drugs and drug targets. Azurin, a bacterial protein with broad potential activity, has been shown to have anticancer, antiviral, antiparasitic, and, recently, antimalarial acti...查看完整摘要 14. Corrigendum to "Management of atypical cartilaginous tumors (ACT): An Italian Sarcoma Group (ISG) consensus document" [Crit. Rev. Oncol. Hematol. 223 (2026) 105358]. [Melanoma] Published Erratum | Critical reviews in oncology/hematology | 2026-06-27 | IF 5.5 AI本勘误修正了ACT管理共识中的若干细节问题，提示临床医师在实际应用中需注意核实最新修正版本，以确保诊疗决策的准确性。 15. SLC7A11 deficiency exacerbates systemic lupus erythematosus by inducing instability and ferroptosis in regulatory T cells. [Skin Diseases] Communications biology | 2026-06-27 | IF 5.2 AISLC7A11可作为SLE疾病活动度的新型生物标志物，其表达水平有望指导临床精准干预策略。摘要Systemic lupus erythematosus (SLE) is an autoimmune disease posing a significant threat to human health. Regulatory T cells (Tregs) are crucial for immune homeostasis. Dysfunction of Tregs have been demonstrated in SLE, but underlying mechanisms remain largely unclear. Here, we observe that peripheral Treg numbers and SLC7A11 expression in Tregs are reduced in SLE, with SLC7A11 levels negatively c...查看完整摘要 16. Adults' intentions to vaccinate children against measles in Canada: findings from a national survey. [Measles] 信函 | Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases | 2026-06-27 | IF 10.9 AI加拿大约三分之一家长对儿童麻疹疫苗接种存在犹豫，提示临床医生需加强疫苗安全性沟通与个性化咨询。 17. Indirect measurement of research misconduct among Iranian postgraduate students of medical sciences using the unmatched count technique. [Communicable Diseases] Research integrity and peer review | 2026-06-27 | IF 10.7 AI伊朗医学研究生研究不端行为发生率高达20%-43%，提示加强医学生伦理教育对保障未来临床研究可信度至关重要。摘要Research misconduct poses a serious threat to academic integrity, particularly in medical sciences. This study aimed to estimate the prevalence of various forms of research misconduct include plagiarism, data fabrication or falsification, authorship misconduct, salami slicing, and purchasing research work among postgraduate students in Iranian medical universities using the Unmatched Count Techniq...查看完整摘要 18. Subtyping OCD based on individual symptom networks: subtype-specific neural dynamics and morphometric similarity linked to molecular profiles. [Obsessive-Compulsive Disorder] Molecular psychiatry | 2026-06-27 | IF 9.6 AI基于个体症状网络的强迫症三亚型分类可指导精准治疗策略：检查/强迫思维为主者需关注额顶网络功能，排序/洗涤为主者应考虑感觉运动-注意网络调节，囤积为主者需针对默认模式网络和炎症机制干预。摘要Obsessive-compulsive disorder (OCD) is clinically heterogeneous, posing challenges for diagnosis and treatment. Individual symptom network-based subtyping could provide the framework for characterizing this heterogeneity. This study developed an individualized symptom network (ISN)-based subtyping framework, leveraging a healthy control dataset (n = 3227) to model the normative symptom network. Ba...查看完整摘要 19. Diabetes Alters Protein Corona to Reprogram Wear Particle-Cell Interaction. [Diabetes Mellitus] Acta biomaterialia | 2026-06-27 | IF 9.4 AI合并糖尿病的骨科植入物患者需加强术后监测，DM-PC有望成为预测和干预此类患者植入物松动风险的生物标志物。摘要The long-term stability of biomedical hard-tissue implants is closely associated with the homeostasis of the surrounding immune microenvironment. Wear particles generated from implants can trigger immune activation, leading to local inflammatory responses and inducing bone destruction, ultimately resulting in implant failure. In addition, in patients with diabetes, chronic metabolic disturbances c...查看完整摘要 20. HIF-1α enhances ferroptosis resistance in anaplastic thyroid carcinoma by suppressing ACSL4-mediated lipid metabolic homeostasis. [Carcinoma] Cellular & molecular biology letters | 2026-06-27 | IF 9.2 AIHIF-1α抑制剂联合PD-1阻断剂可能成为克服ATC铁死亡抵抗、突破免疫治疗耐药的新策略。摘要Anaplastic thyroid carcinoma (ATC) exhibits extreme malignancy with a median survival of less than 6 months. Traditional therapeutic approaches yield limited efficacy, necessitating the urgent identification of novel treatment strategies. The tumor hypoxic microenvironment serves as a key driver of ATC progression and drug resistance, in which the transcription factor hypoxia-inducible factor 1α (...查看完整摘要在小程序获取完整功能收藏文章、管理订阅、查看本期完整摘要与个性化内容，请前往小程序「医研日新」。前往小程序查看更多内容免责声明：仅供学术交流参考，不构成任何医学建议或诊疗指导

2025-05-14

·PRNewswire

Akeso's Penpulimab Approval Intensifies the Competition Among the Other Pharmaceutical Companies Active in the Nasopharyngeal Carcinoma Market | DelveInsight

The FDA has approved Akeso's PD-1 monoclonal antibody, penpulimab-kcqx, for the treatment of recurrent or metastatic non-keratinising nasopharyngeal carcinoma in adults. The approval includes its use as a first-line treatment in combination with platinum-based chemotherapy, as well as a monotherapy option for later-stage metastatic disease. This marks the first FDA approval for a biologic developed in-house by Akeso, signifying the Hong Kong-based company's debut in the US nasopharyngeal carcinoma market. LAS VEGAS, May 14, 2025 /PRNewswire/ -- Nasopharyngeal carcinoma is a rare type of cancer that originates in the nasopharynx, the upper part of the throat behind the nose. It is strongly associated with Epstein-Barr virus (EBV) infection. Unlike many other head and neck cancers, NPC has distinct genetic, viral, and environmental risk factors. As per DelveInsight's analysis, in 2023, there were around 67K incident cases of head and neck cancer and around 2,300 cases of nasopharyngeal cancer in the United States. Due to their location and extent of spread, nasopharyngeal cancers are often not suitable for surgical removal. These cancers are usually managed with a combination of chemotherapy and radiation therapy, often followed by additional chemotherapy. If the cancer recurs, it may be treated with another round of radiation, frequently using brachytherapy. In carefully selected cases, skull base resection may be considered as an alternative to radiation. LOQTORZI (toripalimab-tpzi) is an advanced anti-PD-1 monoclonal antibody that inhibits PD-L1 from binding to the PD-1 receptor at a distinct, high-affinity site, thereby enhancing antitumor immune responses and improving overall survival across multiple cancer types. In October 2023, the FDA approved LOQTORZI in combination with cisplatin and gemcitabine as a first-line treatment for adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma. Additionally, the FDA approved toripalimab-tpzi as a monotherapy for adults with recurrent, unresectable, or metastatic nasopharyngeal carcinoma that has progressed following platinum-based chemotherapy. The combination therapy's efficacy was demonstrated in the JUPITER-02 clinical trial. Learn more about the nasopharyngeal carcinoma treatment options @ Nasopharyngeal Carcinoma Treatment Market In April 2025, the FDA approved penpulimab-kcqx, a distinct PD-1 monoclonal antibody, for use alongside cisplatin or carboplatin and gemcitabine as a first-line treatment for adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma. Additionally, the FDA authorized penpulimab-kcqx as a standalone treatment for adults with metastatic non-keratinizing NPC who have experienced disease progression following platinum-based chemotherapy and at least one other prior therapy. Penpulimab-kcqx was independently developed by Akeso, with further development and commercialization carried out through its joint venture with Chia Tai-Tianqing Pharmaceutical Group. This approval marks the first time an innovative biologic developed internally by Akeso has received FDA clearance, signifying a major milestone. It reflects the strength of the clinical data supporting penpulimab-kcqx and signifies Akeso's successful entry into the US regulatory landscape. The achievement showcases Akeso's innovation in drug development and its dedication to meeting high global standards in pharmaceutical quality. The FDA's decision affirms Akeso's international development and expansion strategy and provides a solid platform for the company to advance its clinical programs in the global therapeutics arena. In China, penpulimab-kcqx is already approved for two uses: as a first-line treatment and as a second-line or later therapy for advanced NPC. The recent US approval introduces a new immunotherapy option for American patients with advanced NPC. This regulatory approval was based on findings from the global Phase III AK105-304 trial and the pivotal AK105-202 study, both of which supported the Biologics License Applications (BLA) for penpulimab-kcqx. These trials confirmed the drug's clinical efficacy and favorable safety profile across different stages of metastatic NPC treatment. AK105-304, a randomized, double-blind international Phase III trial, enrolled patients from various ethnic backgrounds. The results will be presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting. Previously, penpulimab-kcqx had received Breakthrough Therapy Designation (BTD), Orphan Drug Designation (ODD), and Fast Track Designation (FTD) from the FDA, emphasizing the urgent need for effective NPC treatments. To know more about the new treatment for nasopharyngeal carcinoma, visit @ FDA-approved Drugs for Nasopharyngeal Carcinoma Triggered by promising advances in immunotherapy, there has been growing interest in the use of immune checkpoint inhibitors (ICI), specifically anti-programmed death-1 or programmed death-1 ligand (PD-1/PD-L1) therapies in the treatment of nasopharyngeal carcinoma. Some of the drugs in the pipeline include Nana-val (Viracta Therapeutics), Tislelizumab (BeiGene), PRO1160 (Genmab/ProfoundBio), and others. Discover which therapies are expected to grab major nasopharyngeal carcinoma drug market share @ New Medicine for Nasopharyngeal Carcinoma TEVIMBRA is a humanized IgG4 monoclonal antibody targeting PD-1, engineered to reduce its interaction with Fc-gamma (Fcγ) receptors on macrophages. This design supports the immune system's ability to recognize and combat tumors. Preclinical research has shown that when PD-1 antibodies bind to Fcγ receptors on macrophages, it can reduce their anti-tumor efficacy by triggering macrophage-driven destruction of T-effector cells. Nanatinostat, developed by Viracta, is an orally administered histone deacetylase (HDAC) inhibitor with selectivity for certain Class I HDAC isoforms. These isoforms are crucial for reactivating viral genes that are epigenetically suppressed in cancers associated with Epstein-Barr virus (EBV). Nanatinostat is being evaluated as part of an all-oral regimen called Nana-val, in combination with the antiviral valganciclovir, for the treatment of various EBV-related cancers. Discover more about drugs for nasopharyngeal carcinoma in development @ Nasopharyngeal Carcinoma Clinical Trials Market The anticipated launch of these emerging nasopharyngeal carcinoma treatments are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the nasopharyngeal carcinoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the market size for nasopharyngeal carcinoma in the 7MM is expected to grow at a significant CAGR by 2034. This expansion across the 7MM will be due to the rising awareness of the disease and incremental healthcare spending across the world, which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. DelveInsight's latest published market report titled N asopharyngeal Carcinoma Market Insight, Epidemiology, and Market Forecast – 2034 will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the nasopharyngeal carcinoma country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The nasopharyngeal carcinoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Incident Cases of Nasopharyngeal Carcinoma Gender-specific Incident Cases of Nasopharyngeal Carcinoma Age-specific Incident Cases of Nasopharyngeal Carcinoma Stage-specific Incident Cases of Nasopharyngeal Carcinoma Treated Cases of Nasopharyngeal Carcinoma The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM nasopharyngeal carcinoma market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this nasopharyngeal carcinoma market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the nasopharyngeal carcinoma market. Also, stay abreast of the mitigating factors to improve your market position in the nasopharyngeal carcinoma therapeutic space. Related Reports Head and Neck Cancer Market Head and Neck Cancer Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key HNC companies, including CEL-SCI, Junshi Biosciences, Coherus, Exelixis, Immutep S.A.S., Merck Sharp & Dohme LLC, Iovance Biotherapeutics, BeiGene, Akeso, Chia Tai-Tianqing, Kura Oncology, Hoffmann-La Roche, Eli Lilly and Company, among others. Head and Neck Cancer Pipeline Head and Neck Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key HNC companies, including Debiopharm, Merck, GlaxoSmithKline, QBiotics Group Limited, Memgen, Inc., BioNTech, Alentis Therapeutics AG, Beijing CorreGene Biotechnology, Coordination Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Sichuan Baili Pharmaceutical Co., Ltd., TILT Biotherapeutics Ltd., Coherus Biosciences, Inc., among others. Head and Neck Squamous Cell Carcinoma Market Head and Neck Squamous Cell Carcinoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key HNSCC companies, including VCN Biosciences, Moderna Therapeutics, Exelixis, MacroGenics, Nykode Therapeutics, Tizona Therapeutics, Totus Medicines, Turnstone Biologics, Hoffmann-La Roche, Hookipa Pharma, Zenith Epigenetics, HiFiBiO, Nanobiotix, GSK, AstraZeneca, Merus, PureTech Health, Rakuten Medical, Jacobio Pharmaceuticals , among others. Recurrent Head and Neck Squamous Cell Carcinoma Pipeline Recurrent Head and Neck Squamous Cell Carcinoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key recurrent HNSCC companies, including AstraZeneca, Astellas, GlaxoSmithKline, Boehringer Ingelheim, Merck, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

免疫疗法临床3期上市批准快速通道孤儿药

100 项与 Tractinostat 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15419

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
弥漫性大B细胞淋巴瘤	临床2期	美国	Viracta Therapeutics, Inc.	2021-05-28
弥漫性大B细胞淋巴瘤	临床2期	澳大利亚	Viracta Therapeutics, Inc.	2021-05-28
弥漫性大B细胞淋巴瘤	临床2期	巴西	Viracta Therapeutics, Inc.	2021-05-28
弥漫性大B细胞淋巴瘤	临床2期	加拿大	Viracta Therapeutics, Inc.	2021-05-28
弥漫性大B细胞淋巴瘤	临床2期	法国	Viracta Therapeutics, Inc.	2021-05-28
弥漫性大B细胞淋巴瘤	临床2期	德国	Viracta Therapeutics, Inc.	2021-05-28
弥漫性大B细胞淋巴瘤	临床2期	以色列	Viracta Therapeutics, Inc.	2021-05-28
弥漫性大B细胞淋巴瘤	临床2期	意大利	Viracta Therapeutics, Inc.	2021-05-28
弥漫性大B细胞淋巴瘤	临床2期	马来西亚	Viracta Therapeutics, Inc.	2021-05-28
弥漫性大B细胞淋巴瘤	临床2期	新加坡	Viracta Therapeutics, Inc.	2021-05-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05166577 (CTgov)	临床1期	爱泼斯坦-巴尔病毒相关胃癌 \| 晚期恶性实体瘤 \| 平滑肌肉瘤 ... 更多	26	Nanatinostat+Valganciclovir (Dose Cohort 1)	壓鑰築構積築選繭鏇膚 = 繭獵簾壓窪鏇窪醖餘網衊獵鑰淵艱膚鏇壓夢觸 (壓襯蓋鑰繭壓窪獵醖遞, 窪夢網廠繭獵願鹽願構 ~ 壓齋醖膚範鹽構觸鏇範) 更多	-	2025-02-24
				Nanatinostat+Valganciclovir (Dose Cohort 2)	壓鑰築構積築選繭鏇膚 = 衊憲襯鏇憲繭願鬱醖淵衊獵鑰淵艱膚鏇壓夢觸 (壓襯蓋鑰繭壓窪獵醖遞, 襯糧壓獵遞積繭簾顧製 ~ 齋艱獵鹽憲選製簾鬱積) 更多
SOHO2024	N/A	外周T细胞淋巴瘤 \| 爱泼斯坦-巴尔病毒感染	-	Nanatinostat	鑰膚築鏇糧醖鬱壓鹹鹽(窪遞衊範鹽襯願鬱製襯) = most Grade 3-4 TRAEs have been haematologic in nature and generally manageable or reversible with only one Grade 5 TRAE 構願選鏇觸淵鑰夢簾簾 (夢簾窪願夢簾夢餘齋願 ) 更多	-	2024-09-04
				Nanatinostat+Valganciclovir
NCT05011058 \| NCT03397706 (Pubmed)	临床1/2期	爱泼斯坦-巴尔病毒阳性淋巴瘤	55	nanatinostat	築鑰齋襯艱糧廠願製窪(膚襯醖獵齋醖齋醖蓋餘) = 29% 鬱簾膚艱淵獵窪夢膚襯 (衊窪鏇襯壓鏇繭齋顧積 ) 更多	-	2023-08-02